| A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects With MTAP-Deleted Advanced Solid Tumors（G-MAP 101） | Advanced Solid Tumors With MTAP Deletion | Recruiting | Phase 1 | 2026-10-02 | | NCT06796699 |
|---|
| A Study to Evaluate Safety, PK and Efficacy of GH55 in Combination With GH21 in Patients With Solid Tumors | Advanced Solid Tumor Cancer | Not yet recruiting | Phase 1 / Phase 2 | 2026-03-03 | | NCT07446725 |
|---|
| Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GH21 Capsules Combined With D-1553 Tablets in Subjects With Locally Advanced or Metastatic Solid Tumors With the KRASG12C Mutation | Locally Advanced or Metastatic Solid Tumors | Not yet recruiting | Phase 2 | 2026-01-06 | | NCT07318649 |
|---|
| A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GH2616 in Subjects With Advanced Solid Tumor. | Advanced Solid Tumor Cancer | Active, not recruiting | Phase 1 | 2025-12-03 | | NCT07260513 |
|---|
| GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors | Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation | Not yet recruiting | Phase 1 / Phase 2 | 2024-07-08 | | NCT06435455 |
|---|
| A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC | Non-Small Cell Lung Cancer With EGFR Mutation | Recruiting | Phase 1 / Phase 2 | 2024-07-08 | | NCT06306456 |
|---|